The timeline might depend on the responses of the Vaccines and Related Biological Products Advisory Committee (VRBPAC). These committee members are not employed by the FDA, but are independent experts in that area. They may have follow-up questions or, for that matter, have issues with the details of the data presented. Their job is to review the evidence and make a recommendation to the FDA via a vote. Then the FDA considers if they will accept the recommendations and issue an EUA.